New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
05:19 EDTLGND, TGTXLigand signs license agreement with TG Therapeutics for IRAK-4
Ligand Pharmaceuticals (LGND) announced the signing of a license agreement with TG Therapeutics (TGTX) for the development and commercialization of Ligandís Interleukin-1 Receptor Associated Kinase-4 inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1M at date of signing, and is eligible to receive $207M in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.
News For LGND;TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
16:22 EDTTGTXRA Capital reports 8.3% passive stake in TG Therapeutics
October 9, 2014
12:04 EDTTGTXTG Therapeutics management to meet with Roth Capital
Subscribe for More Information
October 8, 2014
11:11 EDTLGNDLigand Q3 pre-announcement unlikely to rally stock, says Cantor
Cantor said its views Ligand's pre-announcement of better than expected Q3 results as no more than "a shuffling of the deck chairs" since the company did not also raise its view for the fiscal year. The firm said it does not expect upward momentum for the stock in the near-term and maintains its Hold rating on the shares.
08:34 EDTLGNDLigand maintains FY14 adjusted EPS $1.50-$1.55, consensus $1.55
Subscribe for More Information
08:33 EDTLGNDLigand sees Q4 revenue $22.5M-$24.5M, consensus $23.54M
08:33 EDTLGNDLigand sees Q3 adjusted EPS 33c-37c, consensus 32c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use